Researchers at King's College London have found that patients prescribed any of the 12 most commonly used antidepressants were 21% more likely to experience an episode of gain weight than those not taking the drugs, (after adjusting for other factors which might affect this result). The full research is published in the BMJ.
They also found that the increased relative risk of weight gain hits its peak after two to three years of continued use and that for patients classified as being of 'normal' weight, the risk of moving to either the overweight or obese categories increased by 29%, compared to those not taking antidepressants.
For patients in the overweight category, the risk of transitioning to the obese category was also 29% higher for those prescribed antidepressants than those not on the drugs.
While previous studies have identified short-term weight gain following the start of antidepressant treatment, this study reveals that the risk of weight gain is elevated and sustained for multiple years after the start of treatment. The King's team analysed the electronic health records of just under 300,000 UK patients - 136,762 men and 157,957 women, from 2004 to 2014.
The group was analysed according to whether or not they had been prescribed an antidepressant in a given year and was made up of patients from all weight categories - from normal with a BMI ranging from 18.5 to 14.9, to super obese - with a BMI of 45.0 or greater*.
During the ten-year follow-up period, any recorded increase in body weight of at least 5% was identified. Because patients took antidepressants intermittently throughout the ten years, researchers assessed the actual time they were at risk in order to calculate the annual risk for the entire cohort.
Weight gain was calculated as an increase of 5% of baseline weight; this equates to approximately half a stone for a 70kg person. Researchers also found that that the annual risk of this weight increase was 8.1 per 100 for the group not taking antidepressants, but 11.2 per 100 for those taking antidepressants.
During the second and third years of treatment (the peak risk period) the chance of a 5% body weight gain for those on antidepressants was at least 46% higher than in the group not taking antidepressants. The risk of weight gain remained elevated for up to six years.
Speaking about the research, lead author Dr Rafael Gafoor from King's College London, said: 'Our results show that antidepressant treatment increases the risk of patients gaining weight over a period of years. From a clinical perspective, these observations reinforce the need for active, tailored and sustained body weight management to go hand in hand with the prescribing of antidepressant treatments.'
'It's important to stress that no patients should stop taking their medication and that if they have any concerns they should speak with their doctor or pharmacist.'
Co-author, Professor of Public Health at King's College London, Martin Gulliford, said "The increasingly widespread use of antidepressants may be contributing to long-term population weight gain with associated health risks.
'These results should be set in the context of increasing body mass index in the general population. Data from the Health Survey of England shows that between 2004 and 2014 the prevalence of obesity increased from 23% to 26%.'
###
Notes to editors:
For more information, to receive a copy of the paper or to speak with the report authors please contact Garfield Myrie in the King's press office at: garfield.myrie@kcl.ac.uk, 0207 848 4334 / 07545 418 898.
* The King's team analysed the electronic health records of just under 300,000 UK patients -The group was made up of patients who were classified as being of normal weight (BMI between 18.5 to 24.9), overweight (25.0 -29.9), simple obesity (35.0-34.9), severe obesity (35 -35.9), morbid obesity (40.0 to 44.9) and super obesity (45.0 or greater).
King's College London
King's College London is one of the top 25 universities in the world (2017/18 QS World University Rankings) and among the oldest in
England. King's has more than 29,600 students (of whom nearly 11,700 are graduate students) from some 150 countries worldwide, and some 8,000 staff.
King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF), eighty-four per cent of research at King's was deemed 'world-leading' or 'internationally excellent' (3* and 4*).
Since our foundation, King's students and staff have dedicated themselves in the service of society. King's will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King's strategic vision for the next 12 years to 2029, which will be the 200th anniversary of the founding of the university.
World-changing ideas. Life-changing impact: https://spotlight.kcl.ac.uk/
About the NIHR Biomedical Research Centre at Guy's and St Thomas' and King's College London
The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy's and St Thomas' NHS Foundation Trust and King's College London works to develop and deliver new medicines and diagnostics to patients, drive research and innovation into the NHS, and provide national systems leadership for maximum impact to patients.
With our research activity organised into nine themes, each holding an individual Athena Swan Silver award highlighting our commitment to equality and diversity, and supported by our interdisciplinary, world leading infrastructure, we are poised to deliver the next step change for the health and wealth of our nation.
For more information, visit http://www.guysandstthomasbrc.nihr.ac.uk/.
About the NIHR
The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research.
Established by the Department of Health, the NIHR:
- funds high quality research to improve health
- trains and supports health researchers
- provides world-class research facilities
- works with the life sciences industry and charities to benefit all
- involves patients and the public at every step
Journal
The BMJ